Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Stephen Harvey Zinner, M.D.

Concepts

This page shows the publications Stephen Zinner has written about Staphylococcus aureus.
Connection Strength

3.506
  1. Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin. Int J Antimicrob Agents. 2018 Dec; 52(6):854-860.
    View in: PubMed
    Score: 0.418
  2. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model. J Antimicrob Chemother. 2017 Nov 01; 72(11):3100-3107.
    View in: PubMed
    Score: 0.394
  3. Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin. J Chemother. 2017 Aug; 29(4):220-226.
    View in: PubMed
    Score: 0.366
  4. Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window. Antimicrob Agents Chemother. 2008 Jun; 52(6):1924-8.
    View in: PubMed
    Score: 0.203
  5. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006 Dec; 58(6):1185-92.
    View in: PubMed
    Score: 0.183
  6. Antistaphylococcal effect related to the area under the curve/MIC ratio in an in vitro dynamic model: predicted breakpoints versus clinically achievable values for seven fluoroquinolones. Antimicrob Agents Chemother. 2005 Jul; 49(7):2642-7.
    View in: PubMed
    Score: 0.167
  7. ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2004 Jul; 54(1):178-86.
    View in: PubMed
    Score: 0.156
  8. Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination. Int J Antimicrob Agents. 2004 May; 23(5):451-6.
    View in: PubMed
    Score: 0.154
  9. In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus. Antimicrob Agents Chemother. 2003 May; 47(5):1604-13.
    View in: PubMed
    Score: 0.144
  10. Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships. Diagn Microbiol Infect Dis. 2001 Aug; 40(4):167-71.
    View in: PubMed
    Score: 0.128
  11. Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin. J Antimicrob Chemother. 2021 06 18; 76(7):1832-1839.
    View in: PubMed
    Score: 0.127
  12. Predicting the antistaphylococcal effects of daptomycin-rifampicin combinations in an in vitro dynamic model. J Antibiot (Tokyo). 2020 02; 73(2):101-107.
    View in: PubMed
    Score: 0.113
  13. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model. J Antimicrob Chemother. 1999 Apr; 43(4):483-90.
    View in: PubMed
    Score: 0.109
  14. Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus. J Chemother. 2017 Oct; 29(5):267-273.
    View in: PubMed
    Score: 0.094
  15. In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2015 Feb; 59(2):1014-9.
    View in: PubMed
    Score: 0.080
  16. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. J Chemother. 2011 Jun; 23(3):140-4.
    View in: PubMed
    Score: 0.063
  17. The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models. J Antimicrob Chemother. 2009 Oct; 64(4):815-20.
    View in: PubMed
    Score: 0.056
  18. Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. Int J Antimicrob Agents. 2009 Mar; 33(3):251-4.
    View in: PubMed
    Score: 0.053
  19. Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. J Antimicrob Chemother. 2008 Nov; 62(5):1065-9.
    View in: PubMed
    Score: 0.052
  20. Concentration-response relationships as a basis for choice of the optimal endpoints of the antimicrobial effect: daptomycin and vancomycin pharmacodynamics with staphylococci in an in vitro dynamic model. Int J Antimicrob Agents. 2007 Feb; 29(2):165-9.
    View in: PubMed
    Score: 0.046
  21. Comparative pharmacodynamics of telithromycin and clarithromycin with Streptococcus pneumoniae and Staphylococcus aureus in an in vitro dynamic model: focus on clinically achievable antibiotic concentrations. Int J Antimicrob Agents. 2005 Sep; 26(3):197-204.
    View in: PubMed
    Score: 0.042
  22. Comparison of tube dilution and microtitre methods for the detection of antibiotic tolerance in strains of Staphylococcus aureus. J Antimicrob Chemother. 1984 May; 13(5):417-21.
    View in: PubMed
    Score: 0.039
  23. In-vitro activity of aztreonam in combination with four other antibiotics against gram-negative bacilli and Staphylococcus aureus. J Antimicrob Chemother. 1984 Apr; 13(4):398-9.
    View in: PubMed
    Score: 0.038
  24. Concentration-dependent changes in the susceptibility and killing of Staphylococcus aureus in an in vitro dynamic model that simulates normal and impaired gatifloxacin elimination. Int J Antimicrob Agents. 2004 Jan; 23(1):60-6.
    View in: PubMed
    Score: 0.038
  25. In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):463-9.
    View in: PubMed
    Score: 0.032
  26. Relationships of the area under the curve/MIC ratio to different integral endpoints of the antimicrobial effect: gemifloxacin pharmacodynamics in an in vitro dynamic model. Antimicrob Agents Chemother. 2001 Mar; 45(3):927-31.
    View in: PubMed
    Score: 0.031
  27. Gemifloxacin and ciprofloxacin pharmacodynamics in an in-vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and doses. Int J Antimicrob Agents. 2000 Dec; 16(4):407-14.
    View in: PubMed
    Score: 0.030
  28. Comparative pharmacodynamics of moxifloxacin and levofloxacin in an in vitro dynamic model: prediction of the equivalent AUC/MIC breakpoints and equiefficient doses. J Antimicrob Chemother. 2000 Nov; 46(5):725-32.
    View in: PubMed
    Score: 0.030
  29. Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model. Antimicrob Agents Chemother. 1999 Mar; 43(3):498-502.
    View in: PubMed
    Score: 0.027
  30. Enhancement of leucocyte killing of resistant bacteria selected during exposure to aminoglycosides or quinolones. J Antimicrob Chemother. 1990 Jun; 25(6):941-8.
    View in: PubMed
    Score: 0.015
  31. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother. 1987 Jul; 31(7):1054-60.
    View in: PubMed
    Score: 0.012
  32. In-vitro studies of antibiotic combinations with special emphasis on the evaluation of newly developed methods. J Antimicrob Chemother. 1986 Mar; 17 Suppl A:1-5.
    View in: PubMed
    Score: 0.011
  33. Efficacy of intermittent versus continuous administration of netilmicin in a two-compartment in vitro model. Antimicrob Agents Chemother. 1985 Mar; 27(3):343-9.
    View in: PubMed
    Score: 0.010
  34. AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin. J Antimicrob Chemother. 2002 Oct; 50(4):533-9.
    View in: PubMed
    Score: 0.009
  35. Serum bactericidal activity of moxalactam and cefotaxime with and without tobramycin against Pseudomonas aeruginosa and Staphylococcus aureus. Antimicrob Agents Chemother. 1981 Oct; 20(4):539-41.
    View in: PubMed
    Score: 0.008
  36. Effect of mixing on rifampin bactericidal activity against staphylococci. Antimicrob Agents Chemother. 1981 Aug; 20(2):267-9.
    View in: PubMed
    Score: 0.008
  37. Cefotaxime and amikacin: results of in vitro and in vivo studies against Gram-negative bacteria and Staphylococcus aureus. EORTC International Antimicrobial Therapy Project Group. J Antimicrob Chemother. 1980 Sep; 6 Suppl A:55-61.
    View in: PubMed
    Score: 0.007
  38. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Antimicrob Agents Chemother. 2000 Apr; 44(4):879-84.
    View in: PubMed
    Score: 0.007
  39. Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection. Antimicrob Agents Chemother. 1994 Oct; 38(10):2351-6.
    View in: PubMed
    Score: 0.005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.